Cagrilintide
Shop CagrilintideAlso called: Cagrilintide UK & Lab UK, Cagrilintide and Semaglutide
Cagrilintide is a lab-made medicine that copies a natural body chemical called amylin. Amylin helps control hunger and blood sugar after meals. It is being studied as a weight-loss treatment for people with obesity. Right now it is not sold as an approved medicine.
In studies, cagrilintide works by turning on two tiny parts of cells called the amylin and calcitonin receptors. Turning these on helps the brain feel full, so animals and people eat less food. In animal tests it lowered body weight and also improved blood fats and insulin levels. Scientists think it may help treat obesity in the future.
There is still a lot we do not know. Most published findings so far come from animal studies, and results in rats do not always match what happens in people. Cagrilintide is not approved by drug regulators, so its safety and long-term effects in humans are still being checked in clinical trials. People should not use it outside of a supervised research or medical setting.
Benefits
What Cagrilintide Helps With
The benefits people report — backed by research.
Weight management (10)
Glycemic & metabolic (6)
More reported benefits (3)
Free: The Peptide Stack Cheat-Sheet
You just read the research on Cagrilintide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
- 2.4 mg each (Cagrilintide 2.4 mg + Semaglutide 2.4 mg) 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Infection risk from impurities in unapproved animal-derived thyroid medicationsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com
- Overtreatment or undertreatment from inconsistent thyroid hormone levelsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ endocrinologyadvisor.com
- NauseaMildReported in 10 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources10Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ peptidedosage.org↗ peptidedeck.com↗ peptidesexplorer.com+6
- VomitingMildReported in 11 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources11Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ withpower.com↗ peptidedosage.org↗ peptidedeck.com+7
- Gastrointestinal / Stomach-related side effectsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Serious side effectsSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get Cagrilintide
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Timeline
History & Milestones
Key moments in Cagrilintide’s research and regulatory timeline — sourced and dated.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of ObesityPublicationJan 1, 2024Related:Cagrilintide
News
Latest on Cagrilintide
Dated, sourced reporting that mentions Cagrilintide.
CagriSema bests tirzepatide for weight loss in type 2 diabetes
Novo Nordisk announced topline results showing CagriSema, a fixed-dose combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide in adults with type 2 diabetes in the REIMAGINE 5 trial (12.4% vs. 9.1% at 60 weeks), while achieving noninferior HbA1c reductions. In the REDEFINE 9 trial, CagriSema led to 21% weight loss at 68 weeks in adults with overweight or obesity without diabetes. These are topline company-announced results from ongoing trial programs.
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
A systematic review and network meta-analysis of 39 studies (33,354 participants) assessed gastrointestinal adverse events of GLP-1 receptor agonists in non-diabetic patients with overweight or obesity. Nausea, vomiting, diarrhea, and constipation were the most common side effects. Orforglipron showed the highest nausea risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. The differing safety profiles can help clinicians tailor weight-loss therapy choices.
Weight loss: New drug CagriSema leads to 14% weight loss in trial
Novo Nordisk's experimental combination therapy CagriSema demonstrated superior weight loss and blood sugar control compared to semaglutide alone in a Phase 3 trial. The drug combines the GLP-1 agonist semaglutide with cagrilintide, an amylin receptor agonist, resulting in a 14.2% reduction in body weight over 68 weeks. These results suggest a potential new standard for treating type 2 diabetes and obesity.
Wondering how Cagrilintide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Related on The Health Stacks
Compare